Related Experiment Video
Updated: Jul 11, 2025

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
CD38 Deficiency Alleviates Diabetic Cardiomyopathy by Coordinately Inhibiting Pyroptosis and Apoptosis
Ling-Fang Wang1, Qian Li1, Ke Wen1
1National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Nanchang University, Nanchang 330031, China.
Insights
CD38 deficiency prevents diabetic cardiomyopathy by reducing cell death through the NAD+/Sirt3/FOXO3a pathway. This finding offers a potential therapeutic target for managing heart complications in diabetes mellitus.
Area of Science:
- Cardiovascular Biology
- Metabolic Diseases
- Molecular Medicine
Background:
- Diabetic cardiomyopathy, a complication of diabetes mellitus, leads to heart failure.
- CD38, an NAD+ hydrolase, is implicated in cardiovascular diseases, but its role in diabetic cardiomyopathy is unclear.
Purpose of the Study:
- To investigate the role of CD38 in the development of diabetic cardiomyopathy.
- To explore the therapeutic potential of CD38 deficiency in mitigating diabetes-induced heart damage.
Main Methods:
- Utilized CD38 knockout (CD38-KO) mice subjected to a high-fat diet and streptozotocin (STZ) injection.
- Assessed cardiac function, cardiomyocyte apoptosis, pyroptosis, and molecular signaling pathways (NAD+/Sirt3/FOXO3a).
Main Results:
- CD38 deficiency significantly protected against diabetic cardiomyopathy, improving cardiac function (ejection fraction, fractional shortening).
- CD38 deficiency reduced cardiomyocyte apoptosis and pyroptosis induced by diabetes or high glucose/palmitic acid.
- Upregulated CD38 and downregulated Sirt3 were observed in diabetic mouse hearts; CD38 deficiency increased Sirt3 and FOXO3a expression.
Conclusions:
- CD38 deficiency ameliorates diabetic cardiomyopathy by inhibiting apoptosis and pyroptosis.
- The protective effect is mediated through the activation of the NAD+/Sirt3/FOXO3a signaling pathway.
Abstract:
Diabetic cardiomyopathy is one of the diabetes mellitus-induced cardiovascular complications that can result in heart failure in severe cases, which is characterized by cardiomyocyte apoptosis, local inflammation, oxidative stress, and myocardial fibrosis. CD38, a main hydrolase of NAD+ in mammals, plays an important role in various cardiovascular diseases, according to our previous studies. However, the role of CD38 in diabetes-induced cardiomyopathy is still unknown. Here, we report that global deletion of the CD38 gene significantly prevented diabetic cardiomyopathy induced by high-fat diet plus streptozotocin (STZ) injection in CD38 knockout (CD38-KO) mice. We observed that CD38 expression was up-regulated, whereas the expression of Sirt3 was down-regulated in the hearts of diabetic mice. CD38 deficiency significantly promoted glucose metabolism and improved cardiac functions, exemplified by increased left ventricular ejection fraction and fractional shortening. In addition, we observed that CD38 deficiency markedly decreased diabetes or high glucose and palmitic acid (HG + PA)-induced pyroptosis and apoptosis in CD38 knockout hearts or cardiomyocytes, respectively. Furthermore, we found that the expression levels of Sirt3, mainly located in mitochondria, and its target gene FOXO3a were increased in CD38-deficient hearts and cardiomyocytes with CD38 knockdown under diabetic induction conditions. In conclusion, we demonstrated that CD38 deficiency protected mice from diabetes-induced diabetic cardiomyopathy by reducing pyroptosis and apoptosis via activating NAD+/Sirt3/FOXO3a signaling pathways.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
The Extrinsic Apoptotic Pathway

